Details for Patent: 10,966,984
✉ Email this page to a colleague
Which drugs does patent 10,966,984 protect, and when does it expire?
Patent 10,966,984 protects COSELA and is included in one NDA.
This patent has fifty-three patent family members in seventeen countries.
Summary for Patent: 10,966,984
| Title: | Transient protection of normal cells during chemotherapy |
| Abstract: | This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders. |
| Inventor(s): | Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Chapel Hill, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC) |
| Assignee: | G1 Therapeutics, Inc. (Research Triangle Park, NC) |
| Application Number: | 16/112,360 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,966,984
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacosmos | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER | ⤷ Sign Up | ||||
| Pharmacosmos | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,966,984
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2906156 | ⤷ Sign Up | |||
| Canada | 2906157 | ⤷ Sign Up | |||
| Canada | 2906166 | ⤷ Sign Up | |||
| Canada | 3152117 | ⤷ Sign Up | |||
| China | 105407723 | ⤷ Sign Up | |||
| China | 105407889 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
